InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...

C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare and progressive kidney diseases that often lead to kidney failure. Both involve overactivity in ...

Restricting calorie intake in species such as mice, rhesus monkeys, and fruit flies has been shown to extend their lifespans.

Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...

Newer FDA-approved treatments for myasthenia gravis (MG) include FcRn blockers and complement inhibitors, which offer ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMGTwo studies ...

Washington: The researchers at the University of Chicago have uncovered a surprising new role for zeaxanthin, a plant-based ...

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.

EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

Alexion to deliver 20 presentations across gMG, NF1 plexiform neurofibromas and neuromyelitis optica spectrum disorder at AAN meeting: Cambridge, UK Saturday, April 11, 2026, 18:0 ...